This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
The U.S. FDA approved Abrocitinib on Sep 9th, 2021, to treat moderate-to-severe atopic dermatitis in adults.
A 2020 JADE Phase 3 trial evaluated the safety and efficacy of Abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor, in adults with moderate to severe atopic dermatitis. The study included an active control arm with dupilumab and found that Abrocitinib significantly improved skin clearance, disease extent, severity, and itch compared to the placebo.
Mechanism of Action of undefined
Abrocitinib is a Janus kinase inhibitor that helps to reduce the activity of the enzyme Janus kinase, which is involved in inflammation. Therefore, it helps to improve the skin condition related to atopic dermatitis in patients.
Uses of undefined
It helps to improve sleep disturbance due to itchiness and overall quality of life. It aids in improving the symptoms of anxiety and depression associated with atopic dermatitis. Abrocitinib is used to treat patients with moderate-to-severe atopic dermatitis or atopic eczema, a chronic skin disease.
undefined Drug administaration and Dosage available
Abrocitinib is available in the form of tablets in doses of 100mg and 200mg. Your healthcare provider will calculate the ideal dose according to your condition.
Warnings, Precautions and Side Effects of undefined
Warnings
Inform your doctor if you're allergic to Abrocitinib, lactose, or any of the ingredients present in the medicine. Consult your doctor if you have a serious infection (tuberculosis) or severe liver problem before using the medicine. It is recommended that you inform your doctor if you are using any immunosuppressant or any other medicine. Inform your doctor if you have a plan to vaccinate or have been recently vaccinated. Consult your doctor if you have a blood clot in the vein of the legs or lungs, a heart problem, or cancer.
Precautions
- Laboratory abnormalities: Laboratory monitoring is recommended due to potential changes in platelets, lymphocytes, and lipids.
- Immunisations: Avoid the use of live vaccines prior to, during, and immediately after Abrocitinib treatment.
- Age-related considerations: The safety and efficacy of the medicine in children below 12 years of age have not been established. Inform your doctor if you are a patient who is 65 years or older. It may increase the risk of infection, heart attack, and certain types of cancer in such patients.
Side Effects
The common side effects that are experienced while you are on the treatment with Abrocitinib are feeling sick in the stomach (nausea), cold sores, vomiting, upper abdominal pain, dizziness, acne, and increased blood creatine phosphokinase level.
Word Of Advice
Drinking enough water is recommended to compensate for the water loss during vomiting. It is recommended to avoid eating junk or oily foods, which can worsen the adverse effects of the drug in patients. Applying a cold compress may reduce the pain and inflammation caused by the cold sores. Consult your doctor if you are going for a blood test; the medicine can interfere with the results obtained by the patients. It is recommended to lie down and take a few minutes of rest until the dizziness passes.
Frequently Asked Question
References
- Pfizer Manufacturing Deutschland GmbH, European Medicines Agency (EMA), [Revised on 18 July 2024] [Accessed on 21 May 2024], QRD Human Product Information Template (medicines.org.uk)
- Sanofi-aventis,. US Food and Drug Administration, FDA [Revised on Jan 2022] [Accessed on 21st May 2024],https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213871s000lbl.pdf
Disclaimer
The drug information on this page is not a substitute for medical advice; it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.
